Rationale for treating community-acquired lower respiratory tract infections with amoxicillin/sulbactam combination through pharmacodynamic analysis in the setting of aminopenicillin-resistant organisms

Journal of Chemotherapy

Volumn 13, Issue 4, 2001, Pages 402-406

  Bantar, C ^a   Nicola, F ^a   Fernandez Canigia, L ^a   Arenoso, H J ^a   Soutric, J ^a   Montoto, M ^a   Blanco, M ^a   Smayevsky, J ^a   Jasovich, A ^a  

^a Laboratorio de Bacteriología   (Argentina)

Author keywords

Amoxicillin sulbactam; Pneumonia; Respiratory infection; lactamase inhibitor

Indexed keywords

AMINOPENICILLIN; AMOXICILLIN; BETA LACTAMASE INHIBITOR; SULBACTAM; TRIFAMOX;

ADULT; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATION; DOSE RESPONSE; DRUG EFFECT; DRUG FORMULATION; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN EXPERIMENT; LOWER RESPIRATORY TRACT INFECTION; MALE; MINIMUM INHIBITORY CONCENTRATION; NORMAL HUMAN; PNEUMONIA; STRAIN DIFFERENCE;

EID: 0034906818     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2001.13.4.402     Document Type: Article

References (13)

1. National hospital discharge survey: Annual summary 1990
2. Prognosis and outcomes of patients with community-acquired pneumonia
3. Dosing of amoxicillin/clavulanate given every 12 hours is as effective as dosing every 8 hours for treatment of lower respiratory tract infection
4. Outpatient treatment of community-acquired pneumonia in adults
5. Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections
6. Pharmacokinetic/pharmacodynamic parameter: Rationale for antibacterial dosing of mice and men
7. In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: Application to breakpoint determinations
8. Two pharmacodynamic models for assessing the efficacy of amoxicillin-clavulanate against experimental respiratory tract infections caused by strains of Streptococcus pneumoniae
9. A pharmacodynamic model to support a twelve-hour dosing interval for amoxicillin/sulbactam, a novel oral combination, in the treatment of community-acquired lower respiratory tract infections
10. Simulation of amoxicillin pharmacokinetics in humans for the prevention of streptococcal endocarditis in rats
11. Practice guidelines for the management of community-acquired pneumonia in adults
12. Canadian guidelines for the initial management of community-acquired pneumonia: An evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society
13. Management of community-acquired pneumonia in the era of pneumococcal resistance: A report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group